A successful K-beauty launch in the United States can be delayed before a product ever reaches a retailer. The import process connects product classification, FDA compliance, customs data, labeling, logistics, and communication among the Korean manufacturer, U.S. importer, and customs broker. A beautiful package and a complete sales plan cannot compensate for an entry record that identifies the wrong manufacturer or a label that creates an unintended drug claim. This guide explains the operational checkpoints that Korean beauty brands and U.S. partners should review before shipping in 2026. It focuses on official FDA import procedures and practical customs preparation, showing which records should agree, where common errors arise, and how to build a repeatable pre-shipment review. It is a planning resource, not legal or customs-broker advice.
How the U.S. Cosmetic Import Process Works
Imported cosmetics must comply with the same federal requirements that apply to cosmetics produced in the United States. The FDA’s official Importing Cosmetics page explains that FDA entry reviewers use information transmitted with the importer’s entry, including the declared manufacturer, importer or consignee, product description, and any relevant Affirmations of Compliance. The agency compares those declarations with information in its internal systems.
For most FDA-regulated shipments, entry information is first submitted to U.S. Customs and Border Protection. CBP transmits the FDA-regulated portion for FDA review. The FDA’s Entry Review guidance says electronic systems screen the data and entries that are not released electronically may be routed for human review. Higher-risk products, incomplete information, or an inability to verify compliance can contribute to further review.
FDA review and customs clearance are connected but not interchangeable. FDA evaluates issues within its jurisdiction, while CBP administers customs entry requirements such as tariff classification, valuation, and country-of-origin matters. A shipment may therefore need more than one agency question resolved. The importer of record and its broker should understand who is responsible for each data field and who will respond if an agency requests documents.
No Routine Cosmetic Premarket Approval
FDA generally does not preapprove cosmetic products or ingredients before marketing, with an important exception for color additives. This does not mean an importer has permission to ship a noncompliant product. FDA states that cosmetics must be safe for consumers under labeled or customary conditions of use and properly labeled. A product that appears adulterated or misbranded may be detained or refused.
Teams should avoid advertising a facility registration, product listing, or entry release as “FDA approval.” Those concepts have different legal meanings. The import file should describe the product accurately without turning administrative identifiers into promotional claims.
The Entry Data That Needs to Match
Declared Manufacturer and Responsible Parties
Start by standardizing the legal identity and address of the actual manufacturer across commercial documents, broker instructions, labels, and relevant FDA records. Brand owner, contract manufacturer, exporter, seller, consignee, and importer are not automatically the same entity. A broker cannot reliably correct conflicting business roles without clear instructions from the parties who know the supply chain.
Create a controlled master record for each facility and trading partner. It should preserve official spelling, address formatting, internal vendor codes, and the role each entity performs. When a manufacturer moves or a corporate name changes, update affected records before the next shipment rather than relying on an explanation after a mismatch triggers questions.
Product Description and Intended Use
The entry description should identify what the item actually is. Generic wording such as “beauty goods” gives reviewers and brokers less useful information than a consistent description such as facial moisturizer, cleansing oil, or cosmetic lip tint. The commercial invoice, item master, label, and broker entry should not tell contradictory stories.
Intended use also affects regulatory status. FDA explains in its Cosmetic, Drug, or Both resource that claims to treat or prevent disease or affect the structure or function of the body can make a product a drug under U.S. law. A serum presented as improving the appearance of dry skin is not described the same way as a product claiming to treat eczema. Review English packaging, inserts, websites, and marketplace listings together because the overall intended use is not limited to one label panel.
Product Codes and Optional Affirmations
FDA entry data may include product codes and Affirmations of Compliance. FDA describes A of C codes as three-letter codes that can help facilitate review; the cosmetics import page notes that submission of cosmetic A of C codes is voluntary. Teams should not guess codes merely to fill a field. The broker should use current FDA instructions and accurate source records.
A useful handoff package gives the filer enough information to classify the product consistently and identify the relevant manufacturer. It also names a person who can quickly answer technical questions. Speed comes from accurate preparation, not from inserting every possible code.
Product and Label Compliance Before Shipping
Ingredients, Restrictions, and Color Additives
A formula accepted in Korea is not automatically compliant in the United States. FDA’s Cosmetics Importers guidance lists unsafe ingredients or contaminants, color-additive violations, restricted ingredients, microbial contamination, labeling problems, and drug claims among common reasons a cosmetic may be refused entry.
Color cosmetics require special care. A color additive must be permitted for the intended cosmetic use, and some colors require certification from FDA batches. Suitability can depend on where the product is applied, so a color permitted for one use may not be permitted around the eye. The formula review should use current U.S. requirements rather than relying only on an international color-index reference or a supplier’s general statement.
English Labeling and Traceable Versions
FDA reviews labeling to determine whether required information is present, properly declared, informative, truthful, and in English, except that Spanish applies in Puerto Rico. Before shipping finished retail units, compare the physical production artwork with the approved U.S. file. A screenshot from an earlier design round is not adequate version control.
Record the artwork version, formula version, lot range, production date, and destination SKU together. This makes it easier to determine which labels are on a shipment and prevents a compliant sample from masking an older production run. If bulk product will be labeled after arrival, do not assume that normal retail-label rules disappear; FDA describes a limited exemption with specific conditions, including documentation and control over movement from the labeling establishment.
Import Alerts and Compliance History
FDA import alerts communicate circumstances in which products may be subject to detention without physical examination. Check current alerts relevant to cosmetics, the manufacturer, product type, and known compliance issue before booking transportation. An alert is not simply a shipping delay notice; it can require evidence showing why the goods are admissible.
Compliance history matters beyond one shipment. Repeated inaccurate data, unresolved violations, or inconsistent manufacturer identities can make future entries harder to explain. Maintain corrective-action records and ensure the manufacturer, importer, and broker are working from the same updated information.
Customs Classification and Origin Preparation
HTS Classification Is Product-Specific
Customs duties and data requirements depend on classification under the Harmonized Tariff Schedule of the United States. Similar-looking beauty products are not necessarily classified identically. Composition, function, presentation, and intended use can affect the analysis. The U.S. International Trade Commission publishes the current Harmonized Tariff Schedule, but selecting a code may require professional judgment.
Do not copy a competitor’s code or reuse a code from a different formula without review. Give the customs broker the product description, ingredient information when relevant, packaging details, intended use, value, and country-of-origin facts. Keep the reasoning and supporting documents with the item master so future entries remain consistent.
Country of Origin, Valuation, and Commercial Documents
Country-of-origin marking and customs valuation are CBP matters. The finished product, retail container, and outer packaging should be reviewed with a customs professional against the applicable rules and exceptions. “Designed in” or a brand’s headquarters location does not replace an accurate origin determination.
The commercial invoice should align with the purchase order, packing list, transport documents, and entry instructions. Product quantities, unit values, currency, seller and buyer details, terms of sale, and descriptions need internal consistency. Samples, testers, free goods, and promotional units still require an appropriate customs treatment; “no commercial value” should not be used as a substitute for a defensible declared value.
A Practical Pre-Shipment Checklist
Thirty Days Before Booking
- Confirm U.S. regulatory classification and review all claims.
- Freeze the U.S. formula, label, and SKU versions.
- Validate manufacturer, responsible-person, importer, and consignee identities.
- Check ingredient restrictions, color-additive permissions, and relevant import alerts.
- Obtain a product-specific classification and duty review from the customs broker.
This stage should end with a written gap list and named owners. If the formula, label, and entry description are still changing independently, the shipment is not operationally ready. J&J TWIN’s Frisco context makes this especially practical: a launch calendar for Texas retailers should include compliance lead time rather than assuming international transit is the only variable.
Before Departure
- Match the physical goods to the approved artwork and item master.
- Reconcile invoice, packing list, quantities, values, lots, and origin information.
- Send complete product and manufacturer data to the broker before filing.
- Designate contacts who can answer FDA, CBP, carrier, or broker questions.
- Store supporting records where the U.S. team can retrieve them promptly.
Use a two-person review for high-impact fields rather than asking one employee to create and approve the same entry packet. A compact shipment dossier should include the approved label, product specification, formula reference, commercial documents, relevant facility or product information, broker instructions, and correspondence about unusual issues.
After Arrival
Track the customs entry and FDA status separately. If FDA requests an examination or records, respond through the proper channel and keep a timeline of submissions. Do not distribute goods merely because the carrier shows arrival. Confirm that required releases have occurred and that no hold or conditional instruction remains.
After release, conduct a short review with the broker. Record discrepancies, questions, and corrections in the item master before the next shipment. This converts each import into a controlled learning cycle instead of repeating the same avoidable problem.
Risks and Limitations
No checklist guarantees electronic release or eliminates the possibility of examination. FDA and CBP may inspect shipments, request information, or take action based on the specific facts, compliance history, risk signals, and current law. Shipping routes, Incoterms, product categories, claims, color additives, and contractual roles can materially change the analysis.
This article does not determine an HTS classification, customs value, origin, duty rate, MoCRA obligation, or legal status for a particular product. Official systems and guidance can change, and the FDA’s import technology has continued to evolve. Verify current requirements close to the shipment date and use qualified customs, regulatory, tax, and legal professionals when the facts require them.
Conclusion & Key Takeaways
Import readiness begins well before cartons leave Korea. The strongest files align manufacturer identity, product description, intended use, formula, label, customs classification, origin, value, and commercial documents. Complete and accurate data gives FDA’s screening process a clearer basis for review, while contradictions create questions that can consume time and inventory budget.
Build one controlled product record, review it across regulatory and customs functions, and give the broker reliable information before filing. Check alerts and label versions, preserve supporting records, and learn from every entry. For K-beauty brands planning durable U.S. growth, disciplined import operations are not back-office paperwork; they are part of customer trust and retail reliability.
